Understanding the Recent Fluctuations of Nektar Therapeutics’s (NKTR) Stock

In the past week, NKTR stock has gone up by 10.10%, with a monthly gain of 25.36% and a quarterly surge of 73.06%. The volatility ratio for the week is 6.69%, and the volatility levels for the last 30 days are 8.64% for Nektar Therapeutics The simple moving average for the last 20 days is 9.92% for NKTR stock, with a simple moving average of 59.63% for the last 200 days.

Is It Worth Investing in Nektar Therapeutics (NASDAQ: NKTR) Right Now?

The stock has a 36-month beta value of 0.91. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 5 as “overweight,” 1 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for NKTR is 178.15M, and at present, short sellers hold a 1.41% of that float. On April 02, 2024, the average trading volume of NKTR was 1.60M shares.

NKTR) stock’s latest price update

Nektar Therapeutics (NASDAQ: NKTR)’s stock price has plunge by 8.15relation to previous closing price of 0.90. Nevertheless, the company has seen a 10.10% surge in its stock price over the last five trading sessions. PRNewsWire reported 2024-03-22 that SAN FRANCISCO, March 22, 2024 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m.

Analysts’ Opinion of NKTR

Jefferies gave a rating of “Hold” to NKTR, setting the target price at $1 in the report published on May 10th of the previous year.

NKTR Trading at 32.53% from the 50-Day Moving Average

After a stumble in the market that brought NKTR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.70% of loss for the given period.

Volatility was left at 8.64%, however, over the last 30 days, the volatility rate increased by 6.69%, as shares surge +9.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +83.49% upper at present.

During the last 5 trading sessions, NKTR rose by +10.49%, which changed the moving average for the period of 200-days by +78.16% in comparison to the 20-day moving average, which settled at $0.8936. In addition, Nektar Therapeutics saw 73.06% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at NKTR starting from ROBIN HOWARD W, who sale 20,033 shares at the price of $0.68 back on Feb 20 ’24. After this action, ROBIN HOWARD W now owns 879,889 shares of Nektar Therapeutics, valued at $13,622 using the latest closing price.

Zalevsky Jonathan, the Chief R&D Officer of Nektar Therapeutics, sale 9,014 shares at $0.68 during a trade that took place back on Feb 20 ’24, which means that Zalevsky Jonathan is holding 265,025 shares at $6,130 based on the most recent closing price.

Stock Fundamentals for NKTR

Current profitability levels for the company are sitting at:

  • -1.81 for the present operating margin
  • 0.63 for the gross margin

The net margin for Nektar Therapeutics stands at -3.06. The total capital return value is set at -0.47. Equity return is now at value -110.95, with -49.80 for asset returns.

Based on Nektar Therapeutics (NKTR), the company’s capital structure generated 0.5 points at debt to capital in total, while cash flow to debt ratio is standing at -1.46. The debt to equity ratio resting at 1.01. The interest coverage ratio of the stock is -6.44.

Currently, EBITDA for the company is -129.61 million with net debt to EBITDA at -1.77. When we switch over and look at the enterprise to sales, we see a ratio of 4.35. The receivables turnover for the company is 40.02for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.45.


To sum up, Nektar Therapeutics (NKTR) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts